Product Name: MetSubtide
Product Number: PE-01BID99
Size: 200 µg      Price:55.00
1 mg      $US110.00
5 mg      241.00
Peptide Name: MetSubtide

Product Use: For assaying the phosphotransferase activity of Hepatocyte growth factor (HGF) receptor-tyrosine kinase (UniProt ID P08581).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: KKGMDKKYYVVPFGG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 1891.23 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid
Storage Conditions: -20°C

Peptide Recommended Enzyme: Met

Scientific Background: Met (HGFR) is a protein-tyrosine kinase of the TK group and Met family. It is activated by binding hepatocyte growth factor (HGF), which induces dimerization and autophosphorylation. Phosphorylation of Y1003 increases phosphotransferase activity and induces interaction with Cbl. Phosphorylation of Y1230 and Y1235 increases phosphotransferase activity. Phosphorylation of Y1234 increases phosphotransferase activity and induces interaction with Grb2. Phosphorylation of S985 inhibits phosphotransferase activity. Phosphorylation of Y1349 inhibits phosphotransferase activity, but induces interaction with FAK, Gab1, Grb2, Met, PIK3R1, PLCG1 and Src. Met mediates scattering, proliferation, survival, and morphogenesis of cells. Some immediate regulators that bind to Met after activation with HGF include PLCG1, PIK3R1, GRB2, SRC, STAT3 or the adapter GAB1. Met is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Hepatocellular carcinoma (HCC) occurs with higher risk in those that have chronic HCV (hepatitis C virus) or HBV (hepatitis B virus) infection, or aflatoxin exposure in diet, or alcohol-induced cirrhosis, or another form of cirrhosis.